Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088928 | 0.84 | ALDH1A1 (0.42) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4840226 | 0.82 | ALOX15 (0.58) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4444751 | 0.82 | ALOX15 (0.40) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14400108 | 0.82 | ALOX15 (0.40) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6720485 | 0.82 | ALOX15 (0.40) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5836728 | 0.80 | ALOX15 (0.39) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6720487 | 0.80 | ALOX15 (0.39) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6790922 | 0.80 | ALOX15 (0.39) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL222761 | 0.80 | ALOX15 (0.39) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17987766 | 0.80 | NAAA (0.47) | ALOX15CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-111655708-B | 2, 3-biphosphinopyrazine derivative, process for producing the same, complex compound, catalyst, and process for producing organoboron compound | 日本化学工业株式会社 | 2023-08-25 | — | — | CN | disclosed |
| CN-111032668-B | Optically active 2,3-bisphosphinylpyrazine derivative, process for producing the same, transition metal complex, and process for producing organoboron compound | 日本化学工业株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11084835-B2 | 2,3-bisphosphinopyrazine derivative, method for producing same, transition metal complex, asymmetric catalyst, and method for producing organic boron compound | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-11053265-B2 | Optically active substituted 2,3-bisphosphinoquinoxalines and processes for producing the same | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20210047351-A1 | 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-02-18 | — | — | US | disclosed |
| US-20200377536-A1 | OPTICALLY ACTIVE 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2020-12-03 | — | — | US | disclosed |
| WO-1998042682-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
| CN-1189824-A | 1-amino-3-benzyluracils | BASF AG (DE) | 1998-08-05 | — | — | CN | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997035845-A1 | SUBSTITUTED 1-METHYL-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-10-02 | — | — | WO | disclosed |
| EP-0790235-A1 | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses | SANKYO COMPANY LIMITED (JP) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993011669-A1 | USE OF 3-PHENYLURACIL DERIVATIVES FOR THE DESICCATION AND ABSCISSION OF PLANT PARTS | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377536-A1 | OPTICALLY ACTIVE 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | ORC3, BMP2, TERT | ALOX15 1139/4885CHRNB2 2932/4885CHRNA4 3322/4885 |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | ALOX15 2278/4885CHRNB2 4538/4885CHRNA4 4272/4885 |
| US-20210047351-A1 | 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, METHOD FOR PRODUCING SAME, TRANSITION METAL COMPLEX, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING ORGANIC BORON COMPOUND | BPGM, COASY, BRSK2 | ALOX15 1608/4885CHRNB2 1680/4885CHRNA4 2293/4885 |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | ALOX15 2278/4885CHRNB2 4538/4885CHRNA4 4272/4885 |
| US-11084835-B2 | 2,3-bisphosphinopyrazine derivative, method for producing same, transition metal complex, asymmetric catalyst, and method for producing organic boron compound | BPGM, BRSK2, COASY | ALOX15 1546/4885CHRNB2 1489/4885CHRNA4 2181/4885 |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | ALOX15 2278/4885CHRNB2 4538/4885CHRNA4 4272/4885 |
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | ALOX15 2278/4885CHRNB2 4538/4885CHRNA4 4272/4885 |
| US-11053265-B2 | Optically active substituted 2,3-bisphosphinoquinoxalines and processes for producing the same | TBXA2R, TBC1D15, P2RY2 | ALOX15 2406/4885CHRNB2 3370/4885CHRNA4 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.